SELLAS Life Sciences Group Files 8-K
Ticker: SLS · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
SELLAS Life Sciences Group filed an 8-K on Jan 23, 2025, covering Reg FD and financials.
AI Summary
On January 23, 2025, SELLAS Life Sciences Group, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Galena Biopharma, Inc. and RXi Pharmaceuticals Corp, is incorporated in Delaware and headquartered at 7 Times Square, New York, NY.
Why It Matters
This 8-K filing provides important updates and disclosures from SELLAS Life Sciences Group, Inc. to the public and investors regarding their financial statements and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report detailing disclosures and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- Galena Biopharma, Inc. (company) — Former Company Name
- RXi Pharmaceuticals Corp (company) — Former Company Name
- January 23, 2025 (date) — Date of Report
- 7 Times Square, New York, NY (location) — Business Address
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 23, 2025.
What are the main items covered in this 8-K filing?
This 8-K filing covers Regulation FD Disclosure and Financial Statements and Exhibits.
What is the state of incorporation for SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group, Inc. is incorporated in Delaware.
What is the business address of SELLAS Life Sciences Group, Inc.?
The business address is 7 Times Square, Suite 2503, New York, NY 10036.
What were some of the former names of SELLAS Life Sciences Group, Inc.?
Some of the former names of SELLAS Life Sciences Group, Inc. include Galena Biopharma, Inc. and RXi Pharmaceuticals Corp.
Filing Stats: 769 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2025-01-23 16:42:03
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm254291d1_8k.htm (8-K) — 28KB
- tm254291d1_ex99-1.htm (EX-99.1) — 21KB
- 0001104659-25-005648.txt ( ) — 227KB
- sls-20250123.xsd (EX-101.SCH) — 3KB
- sls-20250123_lab.xml (EX-101.LAB) — 33KB
- sls-20250123_pre.xml (EX-101.PRE) — 22KB
- tm254291d1_8k_htm.xml (XML) — 4KB
01
ITEM 7.01 REGULATION FD DISCLOSURE. On January 23, 2025, SELLAS Life Sciences Group, Inc. (the "Company") issued a press release (the "Press Release") announcing the outcome of interim analysis conducted by the Independent Data Monitoring Committee ("IDMC") in its Phase 3 REGAL trial of galinpepimut-S ("GPS") in acute myeloid leukemia ("AML"). A copy of the Press Release is included as Exhibit 99.1 hereto and is incorporated by reference herein. The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing. The Press Release contains forward-looking statements. Such forward-looking "estimate," "plan," "project" and other words of similar import. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting the Company and its development programs as set forth under the caption "Risk Factors" in SELLAS' Annual Report on Form 10-K filed on March 28, 2024 and in its other filings
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated January 23, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: January 23, 2025 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer